Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Primary Inclusion criteria:~* diagnosis of idiopathic pulmonary fibrosis~* 40 to 80 years of age~* Forced Vital Capacity ≥ 50% predicted value~* carbon monoxide diffusing capacity (DLco) ≥ 35% predicted value~* either Forced Vital Capacity or carbon monoxide diffusing capacity (DLco) ≤ 90% predicted value~* no improvement in past year~* able to walk 150 meters in 6 minutes and maintain saturation ≥ 83% while on no more than 6 liters per minute supplemental oxygen~Primary Exclusion criteria:~* unable to undergo pulmonary function testing~* evidence of significant obstructive lung disease or airway hyper-responsiveness~* in the clinical opinion of the investigator, the patient is expected to need and be eligible for a lung transplant within 72 weeks of randomization~* active infection~* liver disease~* cancer or other medical condition likely to result in death within 2 years~* diabetes~* pregnancy or lactation~* substance abuse~* personal or family history of long QT syndrome~* other IPF treatment~* unable to take study medication~* withdrawal from other IPF trials

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 2403 mg/day pirfenidone (Type: ACTIVE_COMPARATOR): 2403 mg/day pirfenidone dose group.
- placebo (Type: PLACEBO_COMPARATOR): Placebo equivalent.

Based on this trial design, predict the completion outcome and termination type (if applicable).